Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
SALMETEROL XINAFOATE
Primecrown Ltd.
Pressurised Inhalation Suspension
2002-12-06
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Serevent Inhaler 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose actuation delivers 25 micrograms salmeterol (as xinafoate). 3 PHARMACEUTICAL FORM Pressurised inhalation, suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _ADULTS_ Salmeterol provides long-lasting (12 hour) bronchodilatation in reversible airways obstruction due to asthma, chronic bronchitis, emphysema and COPD. It is suitable for long-term regular twice-daily treatment to control symptoms, but in view of its slower onset of action (10 to 20 minutes) it should not be used to relieve acute asthmatic symptoms, for which a faster acting (within 5 minutes) inhaled bronchodilator (e.g. salbutamol) should be given. Serevent is indicated when a regular bronchodilator is required, and to prevent night-time symptoms and/or day-time fluctuations caused by reversible airways obstruction (e.g. before exercise or unavoidable allergen challenge). Serevent, as twice-daily regular treatment, can replace a short-acting (4-hour) inhaled bronchodilator (e.g. salbutamol), when it is required more than once a day, or an oral bronchodilator (e.g. salbutamol, theophylline). There is no evidence that salmeterol is a replacement for corticosteroids and these should not be stopped or reduced when salmeterol is prescribed. In patients not already receiving anti-inflammatory therapy, this should be considered when starting salmeterol. Patients must be warned not to stop steroid therapy or reduce it without medical advice, even if they feel better on Serevent. Regular treatment of reversible airways obstruction in asthma including long-lasting prevention of exercise-induced bronchospasm. Bronchodilators should not be the only or the main treatment in patie Read the complete document